Efficacy of β-lapachone in pancreatic cancer treatment: Exploiting the novel, therapeutic target NQO1

Cancer Biology and Therapy

Volumn 4, Issue 1, 2005, Pages 95-102

  Ough, Matthew ^c   Lewis, Anne ^c   Bey, Erik A ^e   Gao, Jinming ^e   Ritchie, Justine M ^b   Bornmann, William ^f   Boothman, David A ^e   Oberley, Larry W ^a,b,c   Cullen, Joseph J ^a,b,c,d,e,g  

^a Department of Surgery ^*  (United States)

^b Holden Comprehensive Canter Center   (United States)

^c UNIVERSITY OF IOWA   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e CASE WESTERN RESERVE UNIVERSITY   (United States)

^f MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^g UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

Author keywords

B lapachone; Cyclodextrins; NAD(P)H:quinone oxidoreductase; Pancreatic cancer; Quinones; Reactive oxygen species

Indexed keywords

1,2 NAPHTHOQUINONE; AGAR; BETA LAPACHONE; CYCLODEXTRIN; DICOUMAROL; ENZYME INHIBITOR; MENADIONE; NADPH:QUINONE OXIDOREDUCTASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE DEHYDROGENASE; UNCLASSIFIED DRUG; BETA-LAPACHONE; NAPHTHOQUINONE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CELL GROWTH; CELL PROTECTION; CELL SURVIVAL; CELL VIABILITY; CLONOGENESIS; CONTROLLED STUDY; CYTOTOXICITY; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG INHIBITION; DRUG SOLUBILITY; DRUG TARGETING; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; PANCREAS CANCER; PROGNOSIS; SINGLE DRUG DOSE; TUMOR VOLUME; TUMOR XENOGRAFT; ANIMAL; BIOAVAILABILITY; CELL CULTURE; NUDE MOUSE; PANCREAS TUMOR; PATHOLOGY; XENOGRAFT;

AGED; ANIMALS; BIOLOGICAL AVAILABILITY; CYCLODEXTRINS; HUMANS; MALE; MICE; MICE, NUDE; NAPHTHOQUINONES; PANCREATIC NEOPLASMS; PROGNOSIS; REVERSE TRANSCRIPTASE INHIBITORS; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 24644432026     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics 2002. CA: Cancer J Clin 2002; 52:23-47.
2. Yeo CJ, Cameron JL. Pancreatic cancer. Cur Probl Surg 1999; 36:59-152.
3. Cruz FS, Docampo R, deSouza W. Effect of β-lapachone on hydrogen peroxide production in Trypanosoma cruzi. Acta Trop 1978; 35:35-40.
4. Docampo R, Lopes JN, Cruz FS, Souza W. Trypanosoma cruzi: Ultrastructual and metabolic alterations of epimastigotes by β-lapachone. Exp Parasitol 1977; 42:142-9.
5. Schmidt TJ, Miller-Diener A, Litwack G. β-lapachone, a specific competitive inhibitor of ligand binding to the glucocorticoid receptor. J Biol Chem 1984; 259:9536-4.
6. Planchon SM, Wuerzberger SM, Frydman B, Witiak DT, Hutson P, Church DR, Wilding G, Boothman DA. β-lapachone-mediated apoptosis inhuman promyelocytic leukemia (HL-60) and human prostate cancer cells: A p53-independent response. Cancer Res 1995; 55:3706-11.
7. Pink JJ, Planchon SM, Tagliarino C, Varnes ME, Siegel D, Boothman DA. NAD(P)H: Quinone oxidoreductase activity is the principal determinant of β-lapachone cytotoxicity. J Biol Chem 2000; 275:5416-24.
8. Trush MA, Twerdok LE, Rembish SJ, Zhu H, Li YB. Analysis of target cell susceptibility as a basis for the development of a chemoprotective strategy against benzene-induced hematotoxicities. Environ Health Perspect 1996; 104:1227-34.
9. Siegel D, Ross D. Immunodetection of NQO1 in human tissues. Free Radic Biol Med 2000; 29:246-53.
10. Logsdon CD, Simeone DM, Binkley C, Arumugan T, Greenson JK, Giordano TJ, Misek DE, Hanash S. Molecular profiling of pancreatic adenocarcinoma and chronic pancreatitis identifies multiple genes differentially regulated in pancreatic cancer. Cancer Res 2003; 63:2649-57.
11. 1) induces growth inhibition of pancreatic cancer via a superoxide-mediated mechanism. Cancer Res 2003; 63:5513-20.
12. Larm JA, Vaillant F, Linnane AW, Lawen A. Upregulation of the plasma membrane oxidoreductase as a prerequisite for the viability of human Namalwa ρ° cells. J Biol Chem 1994; 269:30097-100.
13. Brar SS, Kennedy TP, Whorton AR, Sturrock AB, Huecksteadt TP, Ghio AJ, Hoidal JR. Reactive oxygen species from NAD(P)H: Quinone oxidoreductase constitutively activate NF-κB in malignant melanoma cells. Am J Physiol 2001; 280:C659-76.
14. Stella VJ, Rajewski. Cyclodextrins: Their future drug formulation and delivery. Pharm Res 1997; 14:556-67.
15. Loftsson T, Brewster ME. Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization. J Pharm Sci 1996; 85:1017-25.
16. Rajewski RA, Stella VJ. Pharmaceutical applications of cyclodextrins. 2. In vivo drug deliver. J Pharm Sci 1996; 85:1142-69.
17. Irie T, Uekama K. Pharmaceutical applications of cyclodextrins. 3. Toxicological issues and safety evaluation. J Pharm Sci 1997; 86:147-62.
18. Wydert C, Roling B, Liu J, Ritchie JM, Oberley LW, Cullen JJ. Suppression of the malignant phenotype in human pancreatic cancer cells by the overexpression of manganese superoxide dismutase. Molecular Cancer Therapeutics 2003; 2:361-9.
19. Lewis A, Ough M, Li L, Hinkhouse MM, Ritchie JM, Spitz DR, Cullen JJ. Treatment of pancreatic cancer cells with dicumarol induces cytotoxicity and oxidative stress. Clinical Cancer Research 2004; 10:4550-8.
20. Littell RC, Milliken GA, Stroup WW, Wolfinger RD. SAS system for mixed models. Cary, NC: SAS Institute Inc., 1996.
21. Akaike H. Information theory and an extension of the maximum likelihood principle. In: Petrov BN, Csaki F, eds. Second International Symposium on Information Theory. Budapest: Akademiai Kiado, 1973:267-81.
22. Nasongkla N, Wiedmann AF, Bruening A, Beman M, Ray D, Bornmann WG, Boothman DA, Guo J. Enhancement of solubility and bioavailability of β-lapachone using cyclodextrin inclusion complexes. Pharmaceutical Research 2003; 20:1626-33.
23. Li CJ, Li YZ, Pinto AV, Pardee AB. Potent inhibition of tumor survival in vivo by β-lapachone plus taxol: Combining drugs imposes different artificial checkpoints. Proc Nat Acad Sci 1999; 96:13369-74.
24. Burris HA, Moore MJ, Andersen J, Greem MR, Rothenber MI, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarrassoff P, Nelson R, Dorr FA, Stephens CD, von Hoff DD. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreatic cancer: A randomized trial. J Clin Oncol 1997; 15:2403-13.